PHAR today
$12.60-$0.25 (-1.95%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourAscending Triangle
1 hourStrong Bearish
15 minLeaning Bearish
5 minConsolidating
Daily trend turns up above $13.32
Key levels
Resistance$13.77
Resistance$13.14
Support$12.05
Support$11.03
Latest news & SEC filings
ProductU.K. regulator clears Pharming drug Joenja for pediatric APDS use
DealPharming Group expands KL1333 licensing deal with Yungjin Pharm
All PHAR news →About Pharming
Pharming Group is a Dutch biotechnology company based in Leiden that develops and sells medicines for uncommon and very uncommon conditions, mostly involving the immune system and inherited disorders. Its approved therapies are RUCONEST, an intravenous recombinant C1 esterase inhibitor for acute hereditary angioedema attacks, and Joenja (leniolisib), an oral PI3Kδ inhibitor for activated PI3Kδ syndrome. Sales are concentrated in the United States and the United Kingdom, with further approvals across parts of Europe, Australia, Israel, and Japan. Its development programs include leniolisib for other primary immunodeficiencies and a late-stage compound for mitochondrial disorders caused by faulty mitochondrial DNA.
Based on the company's 20-F filed Apr 2, 2026.
Nasdaq · Healthcare
Pharming Group N.V. (PHAR)
What Is the Price Target for PHAR?
SEPT Low Target
$37.00
SEPT Mid Target
$39.00
SEPT High Target
$41.00
Analyst Consensus
$39.00
Is PHAR a Buy or Sell Right Now?
Thesis
- •Revenue growing 26.6% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PHAR.
Start Free Trial →Is PHAR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$30.57
48
Moat Score
NARROW
6/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with PHAR?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PHAR Growth Story
Revenue YoY
26.6%
3yr Revenue CAGR
22.3%
EPS Growth YoY
122.22%
FCF Growth YoY
2187.4%
Revenue Trend
ACCELERATING
Dark Pool Trades for PHAR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PHAR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:12:23 | $13.21 | 2,500 | $$33K | BUY |
| 14:51:49 | $12.90 | 3,912 | $$50K | SELL |
| 14:51:49 | $12.90 | 1,500 | $$19K | SELL |
| 16:49:16 | $12.92 | 2,000 | $$26K | SELL |
| 18:27:54 | $12.31 | 1,900 | $$23K | BUY |
5 dark pool trades shown · $$152K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Pharming Group N.V. (PHAR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PHAR — frequently asked questions
What is PHAR stock price today?
Pharming Group N.V. (PHAR) is at $12.60, down 1.95% (-$0.25) at the Nov 13, 2026 close.
Why is PHAR stock moving today?
Latest PHAR news — Nov 6, 2026: U.K. regulator clears Pharming drug Joenja for pediatric APDS use · Nov 5, 2026: Pharming Group expands KL1333 licensing deal with Yungjin Pharm
What is the PHAR price target?
The average analyst price target for PHAR is $39.00, ranging from $37 to $41, based on 2 analysts. Latest: Canaccord Genuity maintains on Oct 29, 2026.
What do analysts rate PHAR?
Analyst ratings for PHAR: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did PHAR beat earnings?
PHAR last reported on Oct 27, 2026: EPS $0.30 vs $0.15 expected — a beat of 100.0%.
What are PHAR support and resistance levels?
Support: $12.05, $11.03, $9.32. Resistance: $13.14, $13.77, $14.79.
What are insiders doing with PHAR?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on PHAR?
Nov 6, 2026: U.K. regulator clears Pharming drug Joenja for pediatric APDS use · Nov 5, 2026: Pharming Group expands KL1333 licensing deal with Yungjin Pharm